The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Engineered antibody Fc variants with enhanced effector function
Open accessAbstract
Antibody-dependent cell-mediated cytotoxicity, a key effector function for the clinical efficacy of monoclonal antibodies, is mediated primarily through a set of closely related Fcγ receptors with both activating and inhibitory activities. By using computational design algorithms and high-throughput screening, we have engineered a series of Fc variants with optimized Fcγ receptor affinity and specificity. The designed variants display >2 orders of magnitude enhancement of in vitro effector function, enable efficacy against cells expressing low levels of target antigen, and result in increased cytotoxicity in an in vivo preclinical model. Our engineered Fc regions offer a means for improving the next generation of therapeutic antibodies and have the potential to broaden the diversity of antigens that can be targeted for antibody-based tumor therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sequences of proteins of immunological interest
(1984) · Analytical Biochemistry · doi:10.1016/0003-2697(84)90805-4 · Cited by 3,363
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
Regnault, A., Lankar, D., Lacabanne, V., Rodriguez, A., Théry, C., Rescigno, M., Saito, T., Verbeek, S., Bonnerot, C., Ricciardi-Castagnoli, P., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.2.371 · Cited by 898
Uchida, J., Hamaguchi, Y., Oliver, J. A., Ravetch, J. V., Poe, J. C., Haas, K. M., & Tedder, T. F. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040119 · Cited by 642
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
Ross, J. S., Fletcher, J. A., Linette, G. P., Stec, J., Clark, E., Ayers, M., Symmans, W. F., Pusztai, L., & Bloom, K. J. (2003) · The Oncologist · doi:10.1634/theoncologist.8-4-307 · Cited by 610
From the bench to the bedside: ways to improve rituximab efficacy
Cartron, G., Watier, H., Golay, J., & Solal-Celigny, P. (2004) · Blood · doi:10.1182/blood-2004-03-1110 · Cited by 523
Rituximab-Dependent Cytotoxicity by Natural Killer Cells
Dall’Ozzo, S., Tartas, S., Paintaud, G., Cartron, G., Colombat, P., Bardos, P., Watier, H., & Thibault, G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2862 · Cited by 434
Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc
Idusogie, E. E., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Wong, P. Y., Ultsch, M., Meng, Y. G., & Mulkerrin, M. G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.8.4178 · Cited by 424
Kalergis, A. M., & Ravetch, J. V. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020338 · Cited by 372
Dhodapkar, K. M., Krasovsky, J., Williamson, B., & Dhodapkar, M. V. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011097 · Cited by 349
Okazaki, A., Shoji-Hosaka, E., Nakamura, K., Wakitani, M., Uchida, K., Kakita, S., Tsumoto, K., Kumagai, I., & Shitara, K. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.01.007 · Cited by 337
Fc RECEPTORS AND THEIR INTERACTIONS WITH IMMUNOGLOBULINS
Raghavan, M., & Bjorkman, P. J. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.181 · Cited by 314
Dahiyat, B. I., & Mayo, S. L. (1996) · Protein Science · doi:10.1002/pro.5560050511 · Cited by 298
Self-citationNieba, L., Krebber, A., & Plückthun, A. (1996) · Analytical Biochemistry · doi:10.1006/abio.1996.0067 · Cited by 290
Localization of the binding site for the human high-affinity Fc receptor on IgG
Duncan, A. R., Woof, J. M., Partridge, L. J., Burton, D. R., & Winter, G. (1988) · Nature · doi:10.1038/332563a0 · Cited by 288
Immune complex–mediated antigen presentation induces tumor immunity
Rafiq, K., Bergtold, A., & Clynes, R. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215640 · Cited by 232
Interaction sites on human IgG-Fc for FcγR: current models
Jefferis, R., & Lund, J. (2002) · Immunology Letters · doi:10.1016/s0165-2478(02)00019-6 · Cited by 220
Rational design and engineering of therapeutic proteins
Marshall, S. A., Lazar, G. A., Chirino, A. J., & Desjarlais, J. R. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02610-2 · Cited by 201
Self-citationDhodapkar, M. V., Krasovsky, J., & Olson, K. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202491499 · Cited by 170
Molecular Basis for Immune Complex Recognition: A Comparison of Fc-Receptor Structures
Sondermann, P., Kaiser, J. T., & Jacob, U. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4670 · Cited by 147
Recognition of immunoglobulins by Fcγ receptors
Radaev, S., & Sun, P. D. (2002) · Molecular Immunology · doi:10.1016/s0161-5890(02)00036-6 · Cited by 136
Preithner, S., Elm, S., Lippold, S., Locher, M., Wolf, A., da Silva, A. J., Baeuerle, P. A., & Prang, N. S. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2005.07.010 · Cited by 131
Sármay, G., Lund, J., Rozsnyay, Z., Gergely, J., & Jefferis, R. (1992) · Molecular Immunology · doi:10.1016/0161-5890(92)90200-h · Cited by 109
Cohen-Solal, J. F. G. (2004) · Immunology Letters · doi:10.1016/j.imlet.2004.01.012 · Cited by 92
Groh, V., Li, Y. Q., Cioca, D., Hunder, N. N. H., Wang, W., Riddell, S. R., Yee, C., & Spies, T. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501953102 · Cited by 91
Prediction of amino acid sequence from structure
Raha, K., Wollacott, A. M., Italia, M. J., & Desjarlais, J. R. (2000) · Protein Science · doi:10.1110/ps.9.6.1106 · Cited by 88
Fc receptors for IgG and antigen presentation on MHC class I and class II molecules
Amigorena, S., & Bonnerot, C. (1999) · Seminars in Immunology · doi:10.1006/smim.1999.0196 · Cited by 88
Ernst, L. K., Metes, D., Herberman, R. B., & Morel, P. A. (2001) · Journal of Molecular Medicine · doi:10.1007/s00109-001-0294-2 · Cited by 88
A novel PCR-based method for direct Fcγ receptor IIIa (CD16) allotyping
de Straat, F. G. J. L.-V., van der Pol, W.-L., Jansen, M., Sugita, N., Yoshie, H., Kobayashi, T., & van de Winkel, J. G. J. (2000) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00240-4 · Cited by 73
Lysine 322 in the human IgG3 CH2 domain is crucial for antibody dependent complement activation
Thommesen, J. E., Michaelsen, T. E., Løset, G. Å., Sandlie, I., & Brekke, O. H. (2000) · Molecular Immunology · doi:10.1016/s0161-5890(01)00010-4 · Cited by 71
The influence of the hinge region length in binding of human IgG to human Fcγ receptors
Redpath, S., Michaelsen, T. E., Sandlie, I., & Clark, M. (1998) · Human Immunology · doi:10.1016/s0198-8859(98)00075-5 · Cited by 50
Weiner, L. M., & Carter, P. M. (2005) · Nature Biotechnology · doi:10.1038/nbt0505-556 · Cited by 48
Vugmeyster, Y., & Howell, K. (2004) · International Immunopharmacology · doi:10.1016/j.intimp.2004.04.015 · Cited by 31
Immune complex–mediated antigen presentation induces tumor immunity
Rafiq, K., Bergtold, A., & Clynes, R. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215640 · Cited by 30
Cited by
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
“With the availability of antibody variants with enhanced binding to either activating or inhibitory FcγRs, however, it might become possible to integrate an additional activating or inhibitory second signal into the antibody–antigen fusion protei”
BackgroundTherapeutic antibodies: successes, limitations and hopes for the future
Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00190.x · Cited by 1,382
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
Therapeutic antibodies for autoimmunity and inflammation
Chan, A. C., & Carter, P. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2761 · Cited by 837
Metadata
- Authors
- Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C., Chung, H. S., Eivazi, A., Yoder, S. C., Vielmetter, J., Carmichael, D. F., Hayes, R. J., & Dahiyat, B. I.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2006-03-06
- Volume
- 103
- Issue
- 11
- Pages
- 4005-4010
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2143562636
- Cited by
- 803
- References
- 40
- FWCI
- 36.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.